Barry S. Ticho

Co-Founder at Verve Therapeutics, Inc.

Barry S. Ticho

Barry S. Ticho

Co-Founder at Verve Therapeutics, Inc.

Overview
Career Highlights

Verve Therapeutics, Inc.

RelSci Relationships

4799

Number of Boards

3

Birthday

1960

Age

61

Contact Data
Trying to get in touch with Barry S. Ticho? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Barry S. Ticho likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Verve Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Verve Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Verve Therapeutics, Inc.

Relationship likelihood: Strong

Venture Partner at Google Ventures

Relationship likelihood: Strong

Managing Partner at Google Ventures

Relationship likelihood: Strong

Co-Founder at Verve Therapeutics, Inc.

Relationship likelihood: Strong

Venture Partner at ARCH Venture Partners

Relationship likelihood: Strong

Managing Director at Biomatics Capital Management CO LLC

Relationship likelihood: Strong

Chief Financial Officer & Principal Accounting Officer at Stoke Therapeutics, Inc.

Relationship likelihood: Strong

Executive Vice President, Head of Research & Preclinical Development at Stoke Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Barry S. Ticho
Potential Connections via
Relationship Science
You
Barry S. Ticho
Co-Founder at Verve Therapeutics, Inc.
Education
PhD

UCE’s Office of Investments is responsible for managing the University's investment assets, which includes overseeing the endowment to ensure that it benefits both current and future generations of the University of Chicago. They oversee the broad investment strategy and provide input to the development of the strategic and tactical investment policies of the University & UCMC endowments, pension plans and self-insurance trust assets. Their strategy combines qualitative and quantitative analysis, seeking to achieve superior investment performance on a risk-adjusted basis.

Haverford College is a private liberal arts college in Haverford, Pennsylvania. All students of the college are undergraduates and nearly all reside on campus. The college was founded in 1833 by members of the Religious Society of Friends (Quakers), and although the college no longer has a formal religious affiliation, Quaker philosophy still influences campus life. Its enrollment, as of 2018, was 1,353 students. The college offers Bachelor of Arts and Bachelor of Science degrees in 31 majors across humanities, social sciences and natural sciences.

MD

The Pritzker School of Medicine is the M.D. granting unit of the Biological Sciences Division of the University of Chicago. It is located on the University's main campus in the historic Hyde Park neighborhood of Chicago, and matriculated its first class in 1927.As one of the most selective medical schools in the United States, it is currently ranked 10th among research universities for medical education by the US News & World Report.

Career History
Chief Medical Officer
2017 - Current

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Co-Founder
Current

Verve Therapeutics, Inc. is a bio technology company, which focuses to protect the world from heart disease. It researches, develops and manufactures cardiology & genetic medicines. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman and is headquartered in Cambridge, MA.

Head of CV & Metabolic Diseases
Prior - 2017

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Stoke Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Barry S. Ticho. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Barry S. Ticho's profile does not indicate a business or promotional relationship of any kind between RelSci and Barry S. Ticho.